Immunotherapy drug tested against rare adrenal cancer

NCT ID NCT02673333

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests the immunotherapy drug pembrolizumab in 39 people with advanced adrenocortical carcinoma that cannot be removed by surgery. The study aims to see if the drug can shrink or control the cancer. Participants receive pembrolizumab and are monitored for tumor response and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pembrolizumab (immunotherapy drug)
What this could lead to: If successful, this could offer a new treatment option for advanced adrenocortical carcinoma, a rare and aggressive cancer with limited therapies.
What could go wrong: This is a small, early-phase trial (39 people) with no control group. The drug may not shrink tumors in enough patients to be considered promising, and immunotherapy can cause immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADRENOCORTICAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adrenal carcinoma adrenal cortex carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADRENOCORTICAL CARCINOMA

Contacts and locations

Locations

Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
University of Michigan (Data or Specimen Analysis Only)

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.